Cargando…
Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441855/ http://dx.doi.org/10.1186/1742-4690-9-S2-P354 |
| _version_ | 1782243389688774656 |
|---|---|
| author | Katinger, D Wagner, A Luque, I Crespillo, S Conejero-Lara, F Roger, M Martin, C Mouz, N Mourao, S Farsang, A Notka, F Malcolm, K Bosquet, N Le Grand, R Moog, C Cope, A Shattock, R Lewis, DJ El Habib, R |
| author_facet | Katinger, D Wagner, A Luque, I Crespillo, S Conejero-Lara, F Roger, M Martin, C Mouz, N Mourao, S Farsang, A Notka, F Malcolm, K Bosquet, N Le Grand, R Moog, C Cope, A Shattock, R Lewis, DJ El Habib, R |
| author_sort | Katinger, D |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3441855 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2012 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-34418552012-09-18 Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans Katinger, D Wagner, A Luque, I Crespillo, S Conejero-Lara, F Roger, M Martin, C Mouz, N Mourao, S Farsang, A Notka, F Malcolm, K Bosquet, N Le Grand, R Moog, C Cope, A Shattock, R Lewis, DJ El Habib, R Retrovirology Poster Presentation BioMed Central 2012-09-13 /pmc/articles/PMC3441855/ http://dx.doi.org/10.1186/1742-4690-9-S2-P354 Text en Copyright ©2012 Katinger et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Katinger, D Wagner, A Luque, I Crespillo, S Conejero-Lara, F Roger, M Martin, C Mouz, N Mourao, S Farsang, A Notka, F Malcolm, K Bosquet, N Le Grand, R Moog, C Cope, A Shattock, R Lewis, DJ El Habib, R Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans |
| title | Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans |
| title_full | Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans |
| title_fullStr | Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans |
| title_full_unstemmed | Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans |
| title_short | Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans |
| title_sort | liposomal formulation of gp41 derivate with adjuvant mpla: vaccine design, immunogenicity in animals and safety in humans |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441855/ http://dx.doi.org/10.1186/1742-4690-9-S2-P354 |
| work_keys_str_mv | AT katingerd liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT wagnera liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT luquei liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT crespillos liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT conejerolaraf liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT rogerm liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT martinc liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT mouzn liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT mouraos liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT farsanga liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT notkaf liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT malcolmk liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT bosquetn liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT legrandr liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT moogc liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT copea liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT shattockr liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT lewisdj liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans AT elhabibr liposomalformulationofgp41derivatewithadjuvantmplavaccinedesignimmunogenicityinanimalsandsafetyinhumans |